Full Fed. Circ. Won't Rethink Upholding UCB's Vimpat Patent
The full Federal Circuit on Friday shot down a request by multiple generic-drug makers to reconsider a panel's split decision upholding the validity of a UCB Inc. patent covering the epilepsy...To view the full article, register now.
Already a subscriber? Click here to view full article